Oxidative stress in Alzheimer's disease

Neuroscience Bulletin

Volumn 30, Issue 2, 2014, Pages 271-281

  Chen, Zhichun ^a,b   Zhong, Chunjiu ^a,b  

^a ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Alzheimer's disease; antioxidants; metals; oxidative stress; tau; amyloid

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTIOXIDANT; CURCUMIN; DIMEBON; IDEBENONE; LEVACECARNINE; LIPID; METAL; MITOQUINONE MESYLATE; NUCLEIC ACID; PRAMIPEXOLE; PROTEIN; SZETO SCHILLER PEPTIDE; TAU PROTEIN; THIOCTIC ACID; UBIDECARENONE; UBIQUINONE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CLINICAL TRIAL (TOPIC); COGNITION; CORRELATION ANALYSIS; DRUG EFFECT; DRUG TARGETING; GENE MUTATION; HUMAN; INFLAMMATION; LIPID OXIDATION; MITOCHONDRIAL DYNAMICS; MITOCHONDRION; NERVE CELL; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN PHOSPHORYLATION; REVIEW; SYNAPSE; ANIMAL; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; HUMANS; OXIDATIVE STRESS;

EID: 84899895001     PISSN: 16737067     EISSN: 19958218     Source Type: Journal    
DOI: 10.1007/s12264-013-1423-y     Document Type: Review

References (130)

1. Sokoloff L. Energetics of functional activation in neural tissues. Neurochem Res 1999, 24: 321-329. (Pubitemid 29067977)
2. Tholey G, Ledig M. Neuronal and astrocytic plasticity: metabolic aspects. Ann Med Interne (Paris) 1990, 141 Suppl 1: 13-18.
3. Pratico D. Oxidative stress hypothesis in Alzheimer's disease: a reappraisal. Trends Pharmacol Sci 2008, 29: 609-615.
4. Nunomura A, Castellani RJ, Zhu X, Moreira PI, Perry G, Smith MA. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 2006, 65: 631-641. (Pubitemid 44297254)
5. Pocernich C, Butterfield D. Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochim Biophys Acta 2012, 1822(5): 625-630.
6. Behl C, Moosmann B. Antioxidant neuroprotection in Alzheimer's disease as preventive and therapeutic approach. Free Radic Biol Med 2002, 15;33(2):182-191.
7. Moosmann B, Behl C. Antioxidants as treatment for neurodegenerative disorders. Expert Opin Investig Drugs 2002, 11(10): 1407-1435. (Pubitemid 35174938)
8. Torres LL, Quaglio NB, de Souza GT, Garcia RT, Dati LM, Moreira WL, et al. Peripheral oxidative stress biomarkers in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 2011, 26: 59-68.
9. Beal MF. Oxidative damage as an early marker of Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 2005, 26: 585-586. (Pubitemid 40228749)
10. Beal M. Oxidatively modiied proteins in aging and disease. Free Radic Biol Med 2002, 32(9): 797-803. (Pubitemid 34439250)
11. Butterfield D, Kanski J. Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech Ageing Dev 2001, 122(9): 945-962. (Pubitemid 32441616)
12. Zhao Y, Zhao B. Oxidative stress and the pathogenesis of Alzheimer's disease. Oxid Med Cell Longev 2013, 2013: 316523.
13. Lovell MA, Ehmann WD, Butler SM, Markesbery WR. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 1995, 45: 1594-1601.
14. Marcus DL, Thomas C, Rodriguez C, Simberkoff K, Tsai JS, Strafaci JA, et al. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp Neurol 1998, 150: 40-44. (Pubitemid 28146421)
15. Pratico D, Clark CM, Lee VM, Trojanowski JQ, Rokach J, FitzGerald GA. Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 2000, 48: 809-812.
16. Williams TI, Lynn BC, Markesbery WR, Lovell MA. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. Neurobiol Aging 2006, 27: 1094-1099. (Pubitemid 43850642)
17. Omar RA, Chyan YJ, Andorn AC, Poeggeler B, Robakis NK, Pappolla MA. Increased expression but reduced activity of antioxidant enzymes in Alzheimer's disease. J Alzheimers Dis 1999, 1: 139-145.
18. Federico A, Cardaioli E, Da Pozzo P, Formichi P, Gallus GN, Radi E. Mitochondria, oxidative stress and neurodegeneration. J Neurol Sci 2012, 322: 254-262.
19. Yan MH, Wang X, Zhu X. Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. Free Radic Biol Med 2013, 62: 90-101.
20. Ayton S, Lei P, Bush AI. Metallostasis in Alzheimer's disease. Free Radic Biol Med 2013, 62: 76-89.
21. Greenough MA, Camakaris J, Bush AI. Metal dyshomeostasis and oxidative stress in Alzheimer's disease. Neurochem Int 2013, 62: 540-555.
22. Dias-Santagata D, Fulga TA, Duttaroy A, Feany MB. Oxidative stress mediates tau-induced neurodegeneration in Drosophila. J Clin Invest 2007, 117: 236-245. (Pubitemid 46055207)
23. Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol 2002, 156: 1051-1063. (Pubitemid 34839854)
24. Candore G, Bulati M, Caruso C, Castiglia L, Colonna-Romano G, Di Bona D, et al. Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications. Rejuvenation Res 2010, 13: 301-313.
25. Lee YJ, Han SB, Nam SY, Oh KW, Hong JT. Inflammation and Alzheimer's disease. Arch Pharm Res 2010, 33: 1539-1556.
26. Ansari MA, Scheff SW. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J Neuropathol Exp Neurol 2010, 69: 155-167.
27. Manczak M, Mao P, Calkins MJ, Cornea A, Reddy AP, Murphy MP, et al. Mitochondria-targeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. J Alzheimers Dis 2010, 20 Suppl 2: S609-631.
28. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 2004, 430: 631-639. (Pubitemid 39061671)
29. Reddy PH. Mitochondrial oxidative damage in aging and Alzheimer's disease: implications for mitochondrially targeted antioxidant therapeutics. J Biomed Biotechnol 2006, 2006: 31372.
30. Skoumalova A, Hort J. Blood markers of oxidative stress in Alzheimer's disease. J Cell Mol Med 2012, 16: 2291-2300.
31. Soderberg M, Edlund C, Kristensson K, Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 1991, 26: 421-425.
32. Butterfield DA, Reed T, Perluigi M, De Marco C, Coccia R, Cini C, et al. Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci Lett 2006, 397: 170-173.
33. Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, et al. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 2005, 64: 1152-1156.
34. Roberts LJ, 2nd, Montine TJ, Markesbery WR, Tapper AR, Hardy P, Chemtob S, et al. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 1998, 273: 13605-13612. (Pubitemid 28268404)
35. Montine TJ, Markesbery WR, Morrow JD, Roberts LJ, 2nd. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann Neurol 1998, 44: 410-413. (Pubitemid 28421451)
36. Singh M, Dang TN, Arseneault M, Ramassamy C. Role of by-products of lipid oxidation in Alzheimer's disease brain: a focus on acrolein. J Alzheimers Dis 2010, 21: 741-756.
37. Ahmed N, Ahmed U, Thornalley PJ, Hager K, Fleischer G, Munch G. Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. J Neurochem 2005, 92: 255-263. (Pubitemid 40194017)
38. Butterfield DA, Reed TT, Perluigi M, De Marco C, Coccia R, Keller JN, et al. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Res 2007, 1148: 243-248. (Pubitemid 46602178)
39. Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 1994, 36: 747-751. (Pubitemid 24337634)
40. Nunomura A, Perry G, Pappolla MA, Wade R, Hirai K, Chiba S, et al. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci 1999, 19: 1959-1964. (Pubitemid 29133374)
41. Mullaart E, Boerrigter ME, Ravid R, Swaab DF, Vijg J. Increased levels of DNA breaks in cerebral cortex of Alzheimer's disease patients. Neurobiol Aging 1990, 11: 169-173. (Pubitemid 20181893)
42. Grivennikova VG, Vinogradov AD. Generation of superoxide by the mitochondrial Complex I. Biochim Biophys Acta 2006, 1757: 553-561.
43. Tan S, Sagara Y, Liu Y, Maher P, Schubert D. The regulation of reactive oxygen species production during programmed cell death. J Cell Biol 1998, 141: 1423-1432. (Pubitemid 28289917)
44. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, et al. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 2001, 21: 3017-3023. (Pubitemid 32323483)
45. Silva DF, Selfridge JE, Lu J, E L, Cardoso SM, Swerdlow RH. Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention. Adv Pharmacol 2012, 64: 83-126.
46. Mutisya EM, Bowling AC, Beal MF. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J Neurochem 1994, 63: 2179-2184. (Pubitemid 24369993)
47. Anantharaman M, Tangpong J, Keller JN, Murphy MP, Markesbery WR, Kiningham KK, et al. Beta-amyloid mediated nitration of manganese superoxide dismutase: implication for oxidative stress in a APPNLH/NLH X PS-1P264L/P264L double knock-in mouse model of Alzheimer's disease. Am J Pathol 2006, 168: 1608-1618.
48. Casley CS, Canevari L, Land JM, Clark JB, Sharpe MA. Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J Neurochem 2002, 80: 91-100. (Pubitemid 34614581)
49. Wang X, Su B, Siedlak SL, Moreira PI, Fujioka H, Wang Y, et al. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci U S A 2008, 105: 19318-19323.
50. Crouch PJ, Harding SM, White AR, Camakaris J, Bush AI, Masters CL. Mechanisms of A beta mediated neurodegeneration in Alzheimer's disease. Int J Biochem Cell Biol 2008, 40: 181-198. (Pubitemid 350137874)
51. Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH. Mitochondria are a direct site of Aβ accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 2006, 15: 1437-1449.
52. Rodrigues CM, Sola S, Brito MA, Brondino CD, Brites D, Moura JJ. Amyloid beta-peptide disrupts mitochondrial membrane lipid and protein structure: protective role of tauroursodeoxycholate. Biochem Biophys Res Commun 2001, 281: 468-474. (Pubitemid 32928179)
53. Apelt J, Bigl M, Wunderlich P, Schliebs R. Aging-related increase in oxidative stress correlates with developmental pattern of beta-secretase activity and beta-amyloid plaque formation in transgenic Tg2576 mice with Alzheimer-like pathology. Int J Dev Neurosci 2004, 22: 475-484. (Pubitemid 39311436)
54. Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 2006, 15: 1437-1449.
55. Matsuoka Y, Picciano M, La Francois J, Duff K. Fibrillar beta-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer's disease. Neuroscience 2001, 104: 609-613. (Pubitemid 32607413)
56. Takuma K, Yao J, Huang J, Xu H, Chen X, Luddy J, et al. ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. FASEB J 2005, 19: 597-598. (Pubitemid 40471256)
57. Yu T, Robotham JL, Yoon Y. Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc Natl Acad Sci U S A 2006, 103: 2653-2658.
58. Bonda DJ, Wang X, Perry G, Smith MA, Zhu X. Mitochondrial dynamics in Alzheimer's disease: opportunities for future treatment strategies. Drugs Aging 2010, 27: 181-192.
59. Wang X, Su B, Fujioka H, Zhu X. Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer's disease patients. Am J Pathol 2008, 173: 470-482.
60. Baldeiras I, Santana I, Proenca MT, Garrucho MH, Pascoal R, Rodrigues A, et al. Oxidative damage and progression to Alzheimer's disease in patients with mild cognitive impairment. J Alzheimers Dis 2010, 21: 1165-1177.
61. Echtay KS. Mitochondrial uncoupling proteins - what is their physiological role? Free Radic Biol Med 2007, 43: 1351-1371. (Pubitemid 47532367)
62. 2+ through uncoupling proteins. Antioxid Redox Signal 2009, 11: 1805-1818.
63. Piccolo G, Banfi P, Azan G, Rizzuto R, Bisson R, Sandona D, et al. Biological markers of oxidative stress in mitochondrial myopathies with progressive external ophthalmoplegia. J Neurol Sci 1991, 105: 57-60.
64. Smits P, Mattijssen S, Morava E, van den Brand M, van den Brandt F, Wijburg F, et al. Functional consequences of mitochondrial tRNA Trp and tRNA Arg mutations causing combined OXPHOS defects. Eur J Hum Genet 2010, 18: 324-329.
65. Wu SB, Ma YS, Wu YT, Chen YC, Wei YH. Mitochondrial DNA mutation-elicited oxidative stress, oxidative damage, and altered gene expression in cultured cells of patients with MERRF syndrome. Mol Neurobiol 2010, 41: 256-266.
66. Ikawa M, Arakawa K, Hamano T, Nagata M, Nakamoto Y, Kuriyama M, et al. Evaluation of systemic redox states in patients carrying the MELAS A3243G mutation in mitochondrial DNA. Eur Neurol 2012, 67: 232-237.
67. Wong A, Cavelier L, Collins-Schramm HE, Seldin MF, McGrogan M, Savontaus M-L, et al. Differentiation-specific effects of LHON mutations introduced into neuronal NT2 cells. Hum Mol Genet 2002, 11: 431-438. (Pubitemid 34213616)
68. Deibel MA, Ehmann WD, Markesbery WR. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. J Neurol Sci 1996, 143: 137-142. (Pubitemid 26402800)
69. Eskici G, Axelsen PH. Copper and oxidative stress in the pathogenesis of Alzheimer's disease. Biochemistry 2012, 51: 6289-6311.
70. Jomova K, Vondrakova D, Lawson M, Valko M. Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 2010, 345: 91-104.
71. Curtain CC, Ali F, Volitakis I, Cherny RA, Norton RS, Beyreuther K, et al. Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem 2001, 276: 20466-20473.
72. Opazo C, Huang X, Cherny RA, Moir RD, Roher AE, White AR, et al. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H2O2. J Biol Chem 2002, 277: 40302-40308. (Pubitemid 35215603)
73. Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JD, Hanson GR, et al. Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 1999, 274: 37111-37116.
74. Lynch T, Cherny RA, Bush AI. Oxidative processes in Alzheimer's disease: the role of abeta-metal interactions. Exp Gerontol 2000, 35: 445-451. (Pubitemid 30665820)
75. Altamura S, Muckenthaler MU. Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J Alzheimers Dis 2009, 16: 879-895.
76. Pulliam JF, Jennings CD, Kryscio RJ, Davis DG, Wilson D, Montine TJ, et al. Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE. Am J Med Genet B Neuropsychiatr Genet 2003, 119B: 48-53. (Pubitemid 37064053)
77. Honda K, Casadesus G, Petersen RB, Perry G, Smith MA. Oxidative stress and redox-active iron in Alzheimer's disease. Ann N Y Acad Sci 2004, 1012: 179-182. (Pubitemid 38453525)
78. Wan L, Nie G, Zhang J, Luo Y, Zhang P, Zhang Z, et al. beta-Amyloid peptide increases levels of iron content and oxidative stress in human cell and Caenorhabditis elegans models of Alzheimer disease. Free Radic Biol Med 2011, 50: 122-129.
79. Sensi SL, Rapposelli IG, Frazzini V, Mascetra N. Altered oxidant-mediated intraneuronal zinc mobilization in a triple transgenic mouse model of Alzheimer's disease. Exp Gerontol 2008, 43: 488-492.
80. Sensi SL, Paoletti P, Bush AI, Sekler I. Zinc in the physiology and pathology of the CNS. Nat Rev Neurosci 2009, 10: 780-791.
81. Goedert M, Spillantini MG. A century of Alzheimer's disease. Science 2006, 314: 777-781. (Pubitemid 44706636)
82. Petersen RB, Nunomura A, Lee HG, Casadesus G, Perry G, Smith MA, et al. Signal transduction cascades associated with oxidative stress in Alzheimer's disease. J Alzheimers Dis 2007, 11: 143-152. (Pubitemid 47010981)
83. Cente M, Filipcik P, Pevalova M, Novak M. Expression of a truncated tau protein induces oxidative stress in a rodent model of tauopathy. Eur J Neurosci 2006, 24: 1085-1090. (Pubitemid 44268139)
84. David DC, Hauptmann S, Scherping I, Schuessel K, Keil U, Rizzu P, et al. Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J Biol Chem 2005, 280: 23802-23814. (Pubitemid 40884866)
85. Dumont M, Stack C, Elipenahli C, Jainuddin S, Gerges M, Starkova NN, et al. Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice. FASEB J 2011, 25: 4063-4072.
86. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007, 53: 337-351. (Pubitemid 46161268)
87. Elipenahli C, Stack C, Jainuddin S, Gerges M, Yang L, Starkov A, et al. Behavioral improvement after chronic administration of coenzyme Q10 in P301S transgenic mice. J Alzheimers Dis 2012, 28: 173-182.
88. Tuppo EE, Arias HR. The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol 2005, 37: 289-305. (Pubitemid 39330191)
89. El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike JD. Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature 1996, 382: 716-719. (Pubitemid 26282177)
90. Johnstone M, Gearing AJ, Miller KM. A central role for astrocytes in the inflammatory response to beta-amyloid; chemokines, cytokines and reactive oxygen species are produced. J Neuroimmunol 1999, 93: 182-193. (Pubitemid 29051564)
91. Smits HA, Rijsmus A, van Loon JH, Wat JW, Verhoef J, Boven LA, et al. Amyloid-beta-induced chemokine production in primary human macrophages and astrocytes. J Neuroimmunol 2002, 127: 160-168. (Pubitemid 34603587)
92. Luo Y, Sunderland T, Roth GS, Wolozin B. Physiological levels of beta-amyloid peptide promote PC12 cell proliferation. Neurosci Lett 1996, 217: 125-128. (Pubitemid 26358818)
93. Kontush A, Schekatolina S. Vitamin E in Neurodegenerative Disorders: Alzheimer's Disease. Ann N Y Acad Sci 2004, 1031: 249-262. (Pubitemid 40361760)
94. Puzzo D, Privitera L, Leznik E, Fa M, Staniszewski A, Palmeri A, et al. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 2008, 28: 14537-14545.
95. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001, 60: 759-767. (Pubitemid 32678256)
96. Nunomura A, Tamaoki T, Tanaka K, Motohashi N, Nakamura M, Hayashi T, et al. Intraneuronal amyloid beta accumulation and oxidative damage to nucleic acids in Alzheimer disease. Neurobiol Dis 2010, 37: 731-737.
97. Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med 2002, 33: 562-571. (Pubitemid 34874977)
98. Paola D, Domenicotti C, Nitti M, Vitali A, Borghi R, Cottalasso D, et al. Oxidative stress induces increase in intracellular amyloid beta-protein production and selective activation of betaI and betaII PKCs in NT2 cells. Biochem Biophys Res Commun 2000, 268: 642-646. (Pubitemid 30119675)
99. Nunomura A, Perry G, Pappolla MA, Friedland RP, Hirai K, Chiba S, et al. Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J Neuropathol Exp Neurol 2000, 59: 1011-1017.
100. Oda A, Tamaoka A, Araki W. Oxidative stress up-regulates presenilin 1 in lipid rafts in neuronal cells. J Neurosci Res 2010, 88: 1137-1145.
101. Tamagno E, Bardini P, Obbili A, Vitali A, Borghi R, Zaccheo D, et al. Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis 2002, 10: 279-288. (Pubitemid 35217581)
102. Yoo MH, Gu X, Xu XM, Kim JY, Carlson BA, Patterson AD, et al. Delineating the role of glutathione peroxidase 4 in protecting cells against lipid hydroperoxide damage and in Alzheimer's disease. Antioxid Redox Signal 2010, 12: 819-827.
103. Tamagno E, Guglielmotto M, Aragno M, Borghi R, Autelli R, Giliberto L, et al. Oxidative stress activates a positive feedback between the γ- and β-secretase cleavages of the β-amyloid precursor protein. J Neurochem 2008, 104: 683-695.
104. Cole GM, Teter B, Frautschy SA. Neuroprotective effects of curcumin. Adv Exp Med Biol 2007, 595: 197-212.
105. Mandel SA, Amit T, Kalfon L, Reznichenko L, Youdim MB. Targeting multiple neurodegenerative diseases etiologies with multimodal-acting green tea catechins. J Nutr 2008, 138: 1578S-1583S.
106. Smith JV, Luo Y. Studies on molecular mechanisms of Ginkgo biloba extract. Appl Microbiol Biotechnol 2004, 64: 465-472. (Pubitemid 38686154)
107. Dumont M, Wille E, Stack C, Calingasan NY, Beal MF, Lin MT. Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. FASEB J 2009, 23: 2459-2466.
108. Murakami K, Murata N, Noda Y, Tahara S, Kaneko T, Kinoshita N, et al. SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid beta protein oligomerization and memory loss in mouse model of Alzheimer disease. J Biol Chem 2011, 286: 44557-44568.
109. Gamblin TC, King ME, Kuret J, Berry RW, Binder LI. Oxidative regulation of fatty acid-induced tau polymerization. Biochemistry 2000, 39: 14203-14210.
110. Schweers O, Mandelkow EM, Biernat J, Mandelkow E. Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments. Proc Natl Acad Sci U S A 1995, 92: 8463-8467.
111. Melov S, Adlard PA, Morten K, Johnson F, Golden TR, Hinerfeld D, et al. Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS One 2007, 2: e536.
112. Goedert M, Hasegawa M, Jakes R, Lawler S, Cuenda A, Cohen P. Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases. FEBS Lett 1997, 409: 57-62. (Pubitemid 27248567)
113. Wadsworth TL, Bishop JA, Pappu AS, Woltjer RL, Quinn JF. Evaluation of coenzyme Q as an antioxidant strategy for Alzheimer's disease. J Alzheimer Dis 2008, 14: 225-234. (Pubitemid 352040040)
114. Yang X, Dai G, Li G, Yang E. Coenzyme Q10 reduces β-amyloid plaque in an APP/PS1 transgenic mouse model of Alzheimer's disease. J Mol Neurosci 2010, 41: 110-113.
115. Yang X, Yang Y, Li G, Wang J, Yang E. Coenzyme Q10 attenuates β-amyloid pathology in the aged transgenic mice with Alzheimer Presenilin 1 mutation. J Mol Neurosci 2008, 34: 165-171.
116. Gutzmann H, Kuhl KP, Hadler D, Rapp MA. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study. Pharmacopsychiatry 2002, 35: 12-18. (Pubitemid 34135453)
117. Senin U, Parnetti L, Barbagallo-Sangiorgi G, Bartorelli L, Bocola V, Capurso A, et al. Idebenone in senile dementia of Alzheimer type: a multicentre study. Arch Gerontol Geriatr 1992, 15: 249-260. (Pubitemid 23016908)
118. Thal LJ, Grundman M, Berg J, Ernstrom K, Margolin R, Pfeiffer E, et al. Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. Neurology 2003, 61: 1498-1502. (Pubitemid 37505568)
119. Smith RAJ, Murphy MP. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann N Y Acad Sci 2010, 1201: 96-103.
120. Okun I, Tkachenko SE, Khvat A, Mitkin O, Kazey V, Ivachtchenko AV. From anti-allergic to anti-Alzheimer's: molecular pharmacology of Dimebon. Curr Alzheimer Res 2010, 7: 97-112.
121. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008, 372: 207-215. (Pubitemid 351978110)
122. Jones RW. Dimebon disappointment. Alzheimers Res Ther 2010, 2: 25.
123. Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 2008, 28: 110-113.
124. Pettegrew JW, Klunk WE, Panchalingam K, Kanfer JN, McClure RJ. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. Neurobiol Aging 1995, 16: 1-4.
125. Thal LJ, Carta A, Clarke WR, Ferris SH, Friedland RP, Petersen RC, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology 1996, 47: 705-711. (Pubitemid 26307301)
126. Thal LJ, Calvani M, Amato A, Carta A, Group ftA-l-CS. A 1-year controlled trial of acetyl-l-carnitine in early-onset AD. Neurology 2000, 55: 805-810.
127. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A Controlled Trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med1997, 336: 1216-1222. (Pubitemid 27183651)
128. Abramova NA, Cassarino DS, Khan SM, Painter TW, Bennett JP. Inhibition by R(+) or S(-) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastoma. J Neurosci Res 2002, 67: 494-500. (Pubitemid 34117119)
129. Manczak M, Mao P, Calkins MJ, Cornea A, Reddy AP, Murphy MP, et al. Mitochondria-targeted antioxidants protect against amyloid-β toxicity in Alzheimer's disease neurons. J Alzheimer Dis 2010, 20: 609-631.
130. Chen Z, Zhong C. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog Neurobiol 2013, 108: 21-43.